Our collaborators
Collaborating for a new era of medicine
Our work at BioNTech is driven by data and a clear vision: to translate science into survival and improve the health of people worldwide. In order to drive our efforts in developing novel medicines to address cancer, infectious diseases, and other serious diseases, we have established a network of world-class partnerships and collaborations. These alliances are based on strategic alignment and shared goals. By leveraging complementary expertise and resources, we work with our partners and collaborators to accelerate innovation and drive progress.
Partners and collaborators
Meet our valued partners and collaborators who are actively working alongside us to realize our vision and make a positive impact for people around the world.
Autolus Therapeutics
Together with Autolus Therapeutics we are committed to advancing both companies’ autologous CAR-T programs. We have agreed to support the launch and expansion of Autolus’ lead cell therapy product in exchange for royalty payments.
For more information on our cell therapy platform, click here.
Bristol Myers Squibb
We have entered into a global strategic partnership with Bristol Myers Squibb for the co-development and co-commercialization of our investigational PD-L1 x VEGF-A bispecific antibody across numerous solid tumor types. We will work jointly to broaden and accelerate the development of this clinical candidate, aiming to set a new standard of care in multiple tumor types.
Learn more about the candidate developed with Bristol Myers Squibb.
Crescendo Biologics
We established a multi-target discovery collaboration with Crescendo Biologics to develop novel immunotherapies for the treatment of patients with cancer and other diseases. Utilizing Crescendo’s proprietary platform, we aim to develop precision immunotherapies, including mRNA-based antibodies against select targets.
Click here for more information on our antibody platform.
Duality Biologics
Our global strategic partnership with Duality Biologics aims to accelerate the research and development of certain antibody-drug conjugates (ADCs).
Learn more about candidates developed with Duality Biologics
Genentech
We entered a pioneering collaboration with Genentech, a member of the Roche group, to jointly research, develop, manufacture and commercialize an individualized mRNA cancer immunotherapy candidate targeting cancer neoantigens specific to individual patients.
Genevant
We formed a strategic collaboration with Genevant for the development of mRNA-based protein replacement therapies, including certain exclusive licenses to Genevant’s lipid nanoparticle (LNP) drug delivery technology for mRNA-based products directed to specified oncology targets.
For more information on our protein replacement platform, click here.
Genmab
We entered into a license and collaboration agreement with Genmab to develop antibodies that are designed to function as tumor-targeted and dual immunomodulators, by applying Genmab’s proprietary technologies in combination with our joint target identification and product concept expertise. Together, we are also developing antibodies that are designed to enhance pre-existing immunity.
MediLink Therapeutics
We formed a global strategic partnership with MediLink Therapeutics to develop multiple next-generation antibody-drug conjugate (ADC) candidates.
Learn more about the candidates developed with MediLink Therapeutics
OncoC4
We entered into a collaboration with OncoC4 for the research and development of a next-generation anti-CTLA4 monoclonal antibody candidate as monotherapy or combination therapy in various cancer indications.
Regeneron
We have entered into a strategic collaboration with Regeneron to jointly conduct clinical trials for two of our mRNA cancer immunotherapy candidates in combination with a PD-1 inhibitor developed and commercialized by Regeneron.
Ryvu Therapeutics
We entered into a multi-target research collaboration with Ryvu Therapeutics for several small molecule immunotherapy programs. BioNTech and Ryvu Therapeutics jointly undertake drug discovery and research projects to develop multiple small molecule programs directed at targets selected by and exclusively developed for BioNTech.
Siemens
We are partnering with Siemens to enable our fully automated and digitalized cGMP-manufacturing sites for future cancer immunotherapies, should they be successfully developed and approved by regulatory authorities.
For more information on our in-house manufacturing capabilities, click here.
TRON
TRON is a non-profit translational research institute that pursues the development of new diagnostics and drugs to treat cancer and other severe diseases. TRON was founded to facilitate clinical translation of innovative science by interfacing between public and private stakeholders and bridging the gap between research and product development.
Explore more
Pipeline
Sites & subsidiaries
